Treatment with the PADI4 inhibitor GSK484 led to 152 differentially expressed genes, of which 62 genes were downregulated and 90 were upregulated in A549 cancer cells, whereas the KDM6A/B inhibitor, GSK-J4, altered the expression of 190 genes, of which 56 genes were downregulated and 134 were upregulated in A549 cancer cells (FDR < 0.05 and LogFC > 1; <−1) (Table S1). The gene discussed is PADI4; the disease is cancer.